<?xml version='1.0' encoding='UTF-8'?><xml><records><record><source-app name="HighWire" version="7.x">Drupal-HighWire</source-app><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Vinall, Maria</style></author></authors><secondary-authors><author><style face="normal" font="default" size="100%">Wood, Brent L.</style></author></secondary-authors></contributors><titles><title><style face="normal" font="default" size="100%">AALL0434 Treatment Therapy Has Excellent Outcomes in Children With T-ALL</style></title><secondary-title><style face="normal" font="default" size="100%">MD Conference Express</style></secondary-title></titles><dates><year><style  face="normal" font="default" size="100%">2014</style></year><pub-dates><date><style  face="normal" font="default" size="100%">2014-12-01 00:00:00</style></date></pub-dates></dates><pages><style  face="normal" font="default" size="100%">5-6</style></pages><abstract><style  face="normal" font="default" size="100%">Good management of patients with T-lymphoblastic leukemia requires identifying those at higher risk of morbidity and mortality. End-induction minimal residual disease appears to be a useful tool for predicting outcome and managing treatment, while classifying patients according to the presence of early thymic precursor immunophenotype does not improve risk assessment.</style></abstract><number><style face="normal" font="default" size="100%">55</style></number><volume><style face="normal" font="default" size="100%">14</style></volume></record></records></xml>